Beijing Science Sun Pharmaceutical Co Ltd (300485) - Total Assets
Based on the latest financial reports, Beijing Science Sun Pharmaceutical Co Ltd (300485) holds total assets worth CN¥3.36 Billion CNY (≈ $492.03 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Beijing Science Sun Pharmaceutical Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Beijing Science Sun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see 300485 stock market capitalisation for the company's overall valuation and market capitalisation.
Beijing Science Sun Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Beijing Science Sun Pharmaceutical Co Ltd's total assets of CN¥3.36 Billion consist of 47.3% current assets and 52.7% non-current assets. Review Beijing Science Sun Pharmaceutical Co Lt balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 2.5% |
| Accounts Receivable | CN¥42.40 Million | 1.2% |
| Inventory | CN¥68.85 Million | 1.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥411.59 Million | 11.5% |
| Goodwill | CN¥21.87 Million | 0.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Beijing Science Sun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 300485 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beijing Science Sun Pharmaceutical Co Ltd's current assets represent 47.3% of total assets in 2025, a decrease from 64.0% in 2011.
- Cash Position: Cash and equivalents constituted 2.5% of total assets in 2025, down from 45.4% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 5.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 11.5% of total assets.
Beijing Science Sun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Beijing Science Sun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Beijing Science Sun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.23 | 22.95 | 16.51 |
| Quick Ratio | 20.28 | 21.87 | 14.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.52 Billion | CN¥1.69 Billion | CN¥1.41 Billion |
Beijing Science Sun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Beijing Science Sun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.29 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 0.5% |
| Total Assets | CN¥3.57 Billion |
| Market Capitalization | $592.76 Million USD |
Valuation Analysis
Below Book Valuation: The market values Beijing Science Sun Pharmaceutical Co Ltd's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Beijing Science Sun Pharmaceutical Co Ltd's assets grew by 0.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Beijing Science Sun Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual total assets of Beijing Science Sun Pharmaceutical Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.57 Billion ≈ $522.17 Million |
+0.47% |
| 2024-12-31 | CN¥3.55 Billion ≈ $519.75 Million |
-1.94% |
| 2023-12-31 | CN¥3.62 Billion ≈ $530.04 Million |
+1.49% |
| 2022-12-31 | CN¥3.57 Billion ≈ $522.27 Million |
+4.92% |
| 2021-12-31 | CN¥3.40 Billion ≈ $497.77 Million |
+13.73% |
| 2020-12-31 | CN¥2.99 Billion ≈ $437.69 Million |
+6.61% |
| 2019-12-31 | CN¥2.81 Billion ≈ $410.53 Million |
+1.63% |
| 2018-12-31 | CN¥2.76 Billion ≈ $403.96 Million |
+12.52% |
| 2017-12-31 | CN¥2.45 Billion ≈ $359.01 Million |
+10.68% |
| 2016-12-31 | CN¥2.22 Billion ≈ $324.36 Million |
+13.97% |
| 2015-12-31 | CN¥1.94 Billion ≈ $284.59 Million |
+170.73% |
| 2014-12-31 | CN¥718.35 Million ≈ $105.12 Million |
+32.77% |
| 2013-12-31 | CN¥541.04 Million ≈ $79.17 Million |
+36.93% |
| 2012-12-31 | CN¥395.13 Million ≈ $57.82 Million |
+41.24% |
| 2011-12-31 | CN¥279.77 Million ≈ $40.94 Million |
-- |
About Beijing Science Sun Pharmaceutical Co Ltd
Beijing Science Sun Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of injections in China. The company offers products for cardiovascular, cerebrovascular, immunomodulation, and nervous systems, and other drugs. It is also involved in raw materials, solid oral preparations, and health products; extraction of traditional Chinese me… Read more